TABLE 2.
Antibiotic utilization between clinic visits among participants enrolled in the COPD study, Buffalo, NY, April 1994 to June 2014
| Antibiotic group | Antibiotic | No. (%) on antibiotic (n = 1,949)a |
|---|---|---|
| Penicillins | Amoxicillin | 171 (8.8) |
| Amoxicillin/clavulanic acid | 205 (10.5) | |
| Other | 46 (2.4) | |
| Cephalosporins | Cephalexin | 50 (2.6) |
| Ceftriaxone | 46 (2.4) | |
| Other | 66 (3.4) | |
| Macrolides | Azithromycin | 401 (20.6) |
| Clarithromycin | 21 (1.1) | |
| Fluoroquinolones | Ciprofloxacin | 118 (6.1) |
| Levofloxacin | 164 (8.4) | |
| Moxifloxacin | 151 (7.7) | |
| Other | 119 (6.1) | |
| Folate antagonists | Trimethoprim/sulfamethoxazole | 213 (10.9) |
| Lincosamide | Clindamycin | 52 (2.7) |
| Tetracycline | Doxycycline | 39 (2.0) |
a
Antibiotic records were unavailable for 41 subject visits. The following antibiotics used in <20 visits are not included in the table: erythromycin (14 uses), vancomycin (12 uses), metronidazole (10 uses), tetracycline (8 uses), and gentamicin (2 uses).